Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Y4QP
|
||||
| Former ID |
DIB003863
|
||||
| Drug Name |
Research programme: MAP kinase kinase 2 inhibitors, Pfizer
|
||||
| Synonyms |
MAPKAP kinase 2 inhibitors (inflammation); MAPKAP kinase 2 inhibitors (inflammation), Pfizer; MAPKAP kinase 2 inhibitors (inflammation), Wyeth
|
||||
| Indication | Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10:C11, C44, K75.9, M00-M25] | Investigative | [543553] | ||
| Company |
Wyeth
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
C1(=O)C(=C(C1=O)N[C@H](C(=O)O)c1cccc(c1)O)Nc1ccncc1
|
||||
| Target and Pathway | |||||
| Target(s) | MAPKAP kinase 2 | Target Info | Inhibitor | [543553] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | ||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| Serotonin HTR1 Group and FOS Pathway | |||||
| p38 MAPK Signaling Pathway | |||||
| MAPK Signaling Pathway | |||||
| FAS pathway and Stress induction of HSP regulation | |||||
| MAP kinase activation in TLR cascade | |||||
| Regulation of mRNA Stability by Proteins that Bind AU-rich Elements | |||||
| Arachidonic acid metabolism | |||||
| Structural Pathway of Interleukin 1 (IL-1) | |||||
| Regulation of Microtubule Cytoskeleton | |||||
| IL-1 signaling pathway | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| MAPK targets/ Nuclear events mediated by MAP kinases | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.